文献速递自身免疫性与大疱性皮肤病

度普利尤单抗治疗大疱性类天疱疮的真实世界多中心疗效与安全性评价

Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.
PubMed 文献 · Br J Dermatol · 2025-01-01

本研究为西班牙34家医院开展的多中心双向性队列研究,纳入103例接受度普利尤单抗治疗的大疱性类天疱疮患者。结果显示4周内53.4%达完全缓解,52周达95.7%,瘙痒评分4周下降70.0%,52周系统性糖皮质激素用量减少82.1%,不良事件多为轻度。

要点

  • 度普利尤单抗治疗大疱性类天疱疮起效快,4周完全缓解率达53.4%。
  • 52周完全缓解率95.7%,系统性糖皮质激素用量减少82.1%。
  • 病程短和仅皮肤受累者16周应答更佳,药物相关与特发性病例应答无差异。

核心结论

  • 度普利尤单抗治疗大疱性类天疱疮有效、起效快且安全,可减少糖皮质激素和其他治疗的需求。
  • 早期启用和仅皮肤受累预示更好的结局。

研究设计与样本

  • 多中心双向性队列研究,覆盖34家医院。
  • 纳入103例接受度普利尤单抗治疗的大疱性类天疱疮患者,中位年龄77.3岁,58.3%为男性。
  • 97.1%的患者初始剂量为600 mg,随后每2周300 mg。
  • 主要结局为4周内达到完全缓解的比例,定义为研究者总体评估评分0或1。

主要发现

  • 4周内53.4%的患者达到完全缓解,第52周达95.7%。
  • 峰值瘙痒数字评定量表评分第4周下降70.0%,第24周完全控制。
  • 第52周系统性糖皮质激素用量减少82.1%。
  • 病程较短和仅皮肤受累预测16周时更好的应答。

关键数值与推荐

  • 完全缓解定义为研究者总体评估评分0或1。
  • 药物相关大疱性类天疱疮与特发性病例的度普利尤单抗应答率无差异。
  • 度普利尤单抗单药治疗与联合治疗患者的应答率无显著差异。

临床怎么用

  • 度普利尤单抗可作为大疱性类天疱疮的有效治疗选择,尤其适用于传统治疗不适合的老年多病共存患者。
  • 早期启用度普利尤单抗可能获得更好的应答。
  • 治疗中可显著减少系统性糖皮质激素用量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bullous pemphigoid (BP) affects elderly individuals with multiple comorbidities, making conventional treatments unsuitable. OBJECTIVES: Evaluate the effectiveness and safety of dupilumab in the treatment of BP. METHODS: A multicentre ambispective cohort study was conducted across 34 hospitals. Patients with BP treated with dupilumab were included. Most of the patients (97.1%) received an initial 600-mg dose followed by 300 mg every 2 weeks. The primary outcome was the proportion of patients achieving complete remission (CR) within 4 weeks, defined as an Investigator's Global Assessment score of 0 or 1. CR at weeks 16, 24 and 52, adverse events (AEs), reductions in Peak Pruritus Numerical Rating Scale (PP-NRS) and systemic glucocorticoid use were also assessed. RESULTS: The study included 103 patients with a median age of 77.3 years; 58.3% were male. CR was achieved by 53.4% within 4 weeks and 95.7% by week 52. The PP-NRS score reduced by 70.0% by week 4 and was completely controlled by week 24. Thirteen patients presented with AEs, most of which were mild. Systemic glucocorticoid use reduced by 82.1% by week 52. Shorter disease duration and exclusive cutaneous involvement predicted better response at 16 weeks. No differences in response rates to dupilumab were observed between drug-associated BP and idiopathic cases. No significant difference in response rates was observed between patients treated with dupilumab in monotherapy and those receiving dupilumab with concomitant treatments. CONCLUSIONS: Dupilumab is effective, rapid and safe in managing BP, reducing the need for corticosteroids and other treatments. Early initiation and exclusive skin involvement predict better outcomes. Bullous pemphigoid (BP) is an autoimmune skin disease that affects elderly people. BP causes large, fluid-filled blisters on the skin and can be very itchy and uncomfortable. Traditional treatments often use corticosteroids, but these can have serious side-effects, especially for older adults who might have other health conditions. In this study, we wanted to see if dupilumab (a newer drug) is effective and safe for treating BP. Dupilumab has already been approved for other skin conditions and works by blocking certain proteins that cause inflammation. This study was carried out in Spain and involved 34 hospitals. We studied 103 patients treated with dupilumab from August 2020 to February 2024. We tracked their progress for at least 4 weeks, looking at how well the drug worked and any side-effects. We found that more than half of the patients (53.4%) saw their symptoms completely clear up within 4 weeks, and nearly all (95.7%) had clear skin by 52 weeks. Itchiness decreased by 70.0% in the first 4 weeks and was completely gone by week 24 for many patients. The use of corticosteroids dropped significantly, by over 80% within 52 weeks. Finally, we found that only 12.6% of patients had side-effects, mostly mild. Overall, our findings suggest that dupilumab is an effective and safe treatment for BP by reducing symptoms and use of corticosteroids. Patients with a shorter duration of BP and those with only skin symptoms responded the best. This drug offers a promising new option for managing BP.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Planella-Fontanillas N, Bosch-Amate X, Jiménez Antón A, et al. Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. Br J Dermatol. 2025. PMID: 39418120. doi:10.1093/bjd/ljae403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。